Visual Function in Subjects Implanted With Advanced Technology Intraocular Lenses
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28010
- Recruiting
- Clinica Rementeria
-
Contact:
- Inés Contreras
- Phone Number: 34913080808
- Email: contreras@clinicarementeria.es
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria: Bilateral cataract surgery Bilateral implantation of one of the intraocular lens models included in the study
Exclusion Criteria:
Intrasurgical complications Postsurgical complications Ophthalmological disease that limits visual potential as estimated by investigator
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Vivity
Patients who have undergone bilateral implantation of Vivity intraocular lens
|
Cataract surgery with bilateral implantation of the same type of intraocular lens
|
|
Eyhance
Patients who have received bilateral implantation of an Eyhance intraocular lens
|
Cataract surgery with bilateral implantation of the same type of intraocular lens
|
|
EMV
Patients who have undergone bilateral implantation of Vivity intraocular lens
|
Cataract surgery with bilateral implantation of the same type of intraocular lens
|
|
Panoptix
Patients who have undergone bilateral implantation of Panoptix intraocular lens
|
Cataract surgery with bilateral implantation of the same type of intraocular lens
|
|
Rayner Trifocal
Patients who have undergone bilateral implantation of Rayner trifocal intraocular lens
|
Cataract surgery with bilateral implantation of the same type of intraocular lens
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intermediate binocular uncorrected visual acuity
Time Frame: 3-9 months after cataract surgery
|
3-9 months after cataract surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Distance binocular uncorrected visual acuity
Time Frame: 3-9 months after cataract surgery
|
3-9 months after cataract surgery
|
|
Near binocular uncorrected visual acuity
Time Frame: 3-9 months after cataract surgery
|
3-9 months after cataract surgery
|
|
Binocular contrast sensitivity
Time Frame: 3-9 months after cataract surgery
|
3-9 months after cataract surgery
|
|
Halo perception
Time Frame: 3-9 months after cataract surgery
|
3-9 months after cataract surgery
|
|
Self-reported visual function questionnaires
Time Frame: 3-9 months after cataract surgery
|
3-9 months after cataract surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 21/365-O_P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.